Senseonics (SENS) Trading Up 9.7%
Senseonics Holdings Inc (NYSEAMERICAN:SENS)’s share price was up 9.7% during mid-day trading on Friday . The stock traded as high as $2.95 and last traded at $2.94. Approximately 540,754 shares changed hands during trading, an increase of 12% from the average daily volume of 484,823 shares. The stock had previously closed at $2.68.
Separately, Canaccord Genuity reiterated a “buy” rating on shares of Senseonics in a report on Wednesday, November 1st.
The stock has a market cap of $359.66 and a PE ratio of -5.36. The company has a debt-to-equity ratio of 0.76, a quick ratio of 2.81 and a current ratio of 2.93.
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Glenmede Trust Co. NA increased its position in shares of Senseonics by 84.6% during the fourth quarter. Glenmede Trust Co. NA now owns 200,387 shares of the company’s stock valued at $533,000 after acquiring an additional 91,822 shares in the last quarter. Millennium Management LLC increased its position in shares of Senseonics by 15.3% during the fourth quarter. Millennium Management LLC now owns 967,208 shares of the company’s stock valued at $2,573,000 after acquiring an additional 128,658 shares in the last quarter. California State Teachers Retirement System bought a new stake in shares of Senseonics during the fourth quarter valued at approximately $651,000. Perceptive Advisors LLC increased its position in shares of Senseonics by 130.0% during the fourth quarter. Perceptive Advisors LLC now owns 115,000 shares of the company’s stock valued at $306,000 after acquiring an additional 65,000 shares in the last quarter. Finally, Goldman Sachs Group Inc. bought a new stake in shares of Senseonics during the fourth quarter valued at approximately $108,000. 30.66% of the stock is owned by institutional investors.
Senseonics Company Profile
Senseonics Holdings, Inc is a medical technology company. The Company focuses on the design, development and commercialization of glucose monitoring systems. The Company operates through glucose monitoring systems segment. It offers a continuous glucose monitoring (CGM) system, Eversense, which is designed an implantable CGM system designed to continually measure glucose levels in people with diabetes.
Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.